GSK plc GSK reported third-quarter 2025 core earnings of $1.48 per American depositary share (ADS), which beat the Zacks Consensus Estimate of $1.26. Core earnings increased 11% year over year on a ...

GSK now owns the global development and commercialisation rights to Empirico's COPD-targeting (siRNA) oligonucleotide, ...

Yesterday, GSK added a new antibody-drug conjugate to its cancer pipeline via a $358 million agreement with French biotech ...

Mepolizumab significantly reduced healthcare resource utilization, including hospitalizations and emergency department visits, in patients with severe eosinophilic asthma over two years. The treatment ...

Approval based on WAYPOINT Phase III results demonstrating reduced nasal polyp severity and nasal congestion, near-elimination of the need for surgery and significantly reduced systematic ...

On May 18, at the 2025 American Thoracic Society (ATS) International Conference, updated findings from a post hoc analysis poster presentation of the Phase III MATINEE trial (NCT04133909) reinforced ...

GSK plc (LSE/NYSE: LON:GSK), a prominent pharmaceutical company with a market capitalization of $73 billion and impressive gross margins of 72%, announced today that the China National Medical ...

GSK’s GSK phase III study evaluating its blockbuster drug Nucala (mepolizumab), an anti-IL5 biologic, for treating chronic obstructive pulmonary disease (COPD), met its primary endpoint. Data from the ...

GSK (NYSE:GSK) announced Friday that its asthma therapy Nucala (mepolizumab) reached the main goal in a Phase 3 trial for patients with chronic obstructive pulmonary disease (COPD), a common lung ...

(Reuters) -British drugmaker GSK said on Friday that its asthma drug, Nucala, met the main goal of a late-stage study in treating patients with chronic obstructive pulmonary disease (COPD), or ...